Vigabatrin is a selective ABAT (GABA transaminase (T)) inhibitor. Vigabatrin is a structural analog of GABA, but does not bind to GABA receptors. Only the S-enantiomer of Vigabatrin is pharmacologically active. In medicine, Vigabatrin is used to treat epilepsy. As of 2019 Vigabatrin is available as a generic medication. Vigabatrin is also used to treat an inborn GABA metabolism defect through the accumulation of GHB. Vigabatrin lowers GHV levels through its inhibition of GABA transaminase.
1. Lippert, B., Metcalf, B.W., Jung, M.J., et al.4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur. J. Biochem. 74(3), 441-445 (1977).
2. Jung, M.J., Lippert, B., Metcalf, B.W., et al.g-Vinyl GABA (4-amino-hex-5-enoic acid), A new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in mice. J. Neurochem. 29(5), 797-802 (1977).
3. Meldrum, B.S., and Murugaiah, K.Anticonvulsant action in mice with sound-induced seizures of the optical isomers of g-vinyl GABA. Eur. J. Pharm. 89(1-2), 149-152 (1983).
4. Luszczki, J.J., and Czuczwar, S.J.Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(2), 529-538 (2007).
See how others have used Vigabatrin (CAS 60643-86-9). Click on the entry to view the PubMed entry .
PMID: # 29396367 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1076: 44-53.
PMID: # 32666325 AAPS PharmSciTech. 196.